Lysophosphatidic acid production and action: Validated targets in cancer?

Makiko Umezu-Goto, Janos Tanyi, John Lahad, Shuying Liu, Shuangxing Yu, Ruth Lapushin, Yutaka Hasegawa, Yiling Lu, Rosanne Trost, Therese Bevers, Eric Jonasch, Ken Aldape, Jinsong Liu, Robyn D. James, Colin G. Ferguson, Yong Xu, Glenn D. Prestwich, Gordon Mills

Research output: Contribution to journalArticle

74 Citations (Scopus)

Abstract

The completion of the human genome project, the evolution of transcriptional profiling and the emergence of proteomics have focused attention on these areas in the pathophysiology and therapy of cancer. The role of lysophospholipids as potential mediators in cancer pathophysiology, screening and management has taken a major leap forward with the recent cloning of several enzymes involved in the metabolism of lysophospholipids. Lysophospholipids, although small molecules, contain a high "informational" content. Differences include the nature of the phosphate head group, the regiochemistry of the fatty acyl chain on the glyceryl backbone, the presence of ether versus ester linkages to the backbone, and the length and saturation of the fatty acyl or alkyl chain. This informational content is sufficient to result in a marked structure function activity relationship at their cognate receptors. Thus the emerging discipline of "functional lipidomics" is likely to prove as important as genomics and proteomics in terms of early diagnosis, prognosis, and therapy. Lysophospholipid levels are elevated in vivo in a number of pathophysiological states including ascitic fluid from ovarian cancer patients indicating a role in the pathophysiology of this devastating disease. Although controversial, levels of specific lysophospholipids may be altered in the blood of cancer patients providing a potential mechanism for early diagnosis. Several of the enzymes involved in the metabolism of lysophospholipids are aberrant in ovarian and other cancers. Further, the enzymes are active in the interstitial space, rendering them readily accessible to the effects of inhibitors including antibodies, proteins, and small molecules. In support of a role for lysophospholipids in the pathophysiology of cancer, expression of receptors for lysophospholipids is also aberrant in cancer cells from multiple different lineages. All of the cell surface receptors for lysophospholipids belong to the G protein coupled receptor family. As over 40% of all drugs in current use target this family of receptors, lysophospholipid receptors are highly "druggable." Indeed, a number of highly specific agonists and antagonists of lysophospholipid receptors have been identified. A number are in preclinical evaluation as therapeutics. We look forward to the next several years when the role of lysophospholipids in physiology and the pathophysiology and management of cancer and other diseases are fully elucidated.

Original languageEnglish (US)
Pages (from-to)1115-1140
Number of pages26
JournalJournal of Cellular Biochemistry
Volume92
Issue number6
DOIs
StatePublished - Dec 1 2004
Externally publishedYes

Fingerprint

Lysophospholipids
Lysophospholipid Receptors
Neoplasms
Metabolism
Proteomics
Ovarian Neoplasms
Early Diagnosis
Enzymes
Human Genome Project
lysophosphatidic acid
Molecules
Cloning
Ascitic Fluid
Physiology
Cell Surface Receptors
Structure-Activity Relationship
G-Protein-Coupled Receptors
Secondary Prevention
Genomics
Early Detection of Cancer

Keywords

  • Autotaxin
  • Cancer
  • Lysophosphatidic acid
  • Treatment

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Cell Biology

Cite this

Lysophosphatidic acid production and action : Validated targets in cancer? / Umezu-Goto, Makiko; Tanyi, Janos; Lahad, John; Liu, Shuying; Yu, Shuangxing; Lapushin, Ruth; Hasegawa, Yutaka; Lu, Yiling; Trost, Rosanne; Bevers, Therese; Jonasch, Eric; Aldape, Ken; Liu, Jinsong; James, Robyn D.; Ferguson, Colin G.; Xu, Yong; Prestwich, Glenn D.; Mills, Gordon.

In: Journal of Cellular Biochemistry, Vol. 92, No. 6, 01.12.2004, p. 1115-1140.

Research output: Contribution to journalArticle

Umezu-Goto, M, Tanyi, J, Lahad, J, Liu, S, Yu, S, Lapushin, R, Hasegawa, Y, Lu, Y, Trost, R, Bevers, T, Jonasch, E, Aldape, K, Liu, J, James, RD, Ferguson, CG, Xu, Y, Prestwich, GD & Mills, G 2004, 'Lysophosphatidic acid production and action: Validated targets in cancer?', Journal of Cellular Biochemistry, vol. 92, no. 6, pp. 1115-1140. https://doi.org/10.1002/jcb.20113
Umezu-Goto M, Tanyi J, Lahad J, Liu S, Yu S, Lapushin R et al. Lysophosphatidic acid production and action: Validated targets in cancer? Journal of Cellular Biochemistry. 2004 Dec 1;92(6):1115-1140. https://doi.org/10.1002/jcb.20113
Umezu-Goto, Makiko ; Tanyi, Janos ; Lahad, John ; Liu, Shuying ; Yu, Shuangxing ; Lapushin, Ruth ; Hasegawa, Yutaka ; Lu, Yiling ; Trost, Rosanne ; Bevers, Therese ; Jonasch, Eric ; Aldape, Ken ; Liu, Jinsong ; James, Robyn D. ; Ferguson, Colin G. ; Xu, Yong ; Prestwich, Glenn D. ; Mills, Gordon. / Lysophosphatidic acid production and action : Validated targets in cancer?. In: Journal of Cellular Biochemistry. 2004 ; Vol. 92, No. 6. pp. 1115-1140.
@article{923e9036dfdd4ab08f6b0185fa6042dd,
title = "Lysophosphatidic acid production and action: Validated targets in cancer?",
abstract = "The completion of the human genome project, the evolution of transcriptional profiling and the emergence of proteomics have focused attention on these areas in the pathophysiology and therapy of cancer. The role of lysophospholipids as potential mediators in cancer pathophysiology, screening and management has taken a major leap forward with the recent cloning of several enzymes involved in the metabolism of lysophospholipids. Lysophospholipids, although small molecules, contain a high {"}informational{"} content. Differences include the nature of the phosphate head group, the regiochemistry of the fatty acyl chain on the glyceryl backbone, the presence of ether versus ester linkages to the backbone, and the length and saturation of the fatty acyl or alkyl chain. This informational content is sufficient to result in a marked structure function activity relationship at their cognate receptors. Thus the emerging discipline of {"}functional lipidomics{"} is likely to prove as important as genomics and proteomics in terms of early diagnosis, prognosis, and therapy. Lysophospholipid levels are elevated in vivo in a number of pathophysiological states including ascitic fluid from ovarian cancer patients indicating a role in the pathophysiology of this devastating disease. Although controversial, levels of specific lysophospholipids may be altered in the blood of cancer patients providing a potential mechanism for early diagnosis. Several of the enzymes involved in the metabolism of lysophospholipids are aberrant in ovarian and other cancers. Further, the enzymes are active in the interstitial space, rendering them readily accessible to the effects of inhibitors including antibodies, proteins, and small molecules. In support of a role for lysophospholipids in the pathophysiology of cancer, expression of receptors for lysophospholipids is also aberrant in cancer cells from multiple different lineages. All of the cell surface receptors for lysophospholipids belong to the G protein coupled receptor family. As over 40{\%} of all drugs in current use target this family of receptors, lysophospholipid receptors are highly {"}druggable.{"} Indeed, a number of highly specific agonists and antagonists of lysophospholipid receptors have been identified. A number are in preclinical evaluation as therapeutics. We look forward to the next several years when the role of lysophospholipids in physiology and the pathophysiology and management of cancer and other diseases are fully elucidated.",
keywords = "Autotaxin, Cancer, Lysophosphatidic acid, Treatment",
author = "Makiko Umezu-Goto and Janos Tanyi and John Lahad and Shuying Liu and Shuangxing Yu and Ruth Lapushin and Yutaka Hasegawa and Yiling Lu and Rosanne Trost and Therese Bevers and Eric Jonasch and Ken Aldape and Jinsong Liu and James, {Robyn D.} and Ferguson, {Colin G.} and Yong Xu and Prestwich, {Glenn D.} and Gordon Mills",
year = "2004",
month = "12",
day = "1",
doi = "10.1002/jcb.20113",
language = "English (US)",
volume = "92",
pages = "1115--1140",
journal = "Journal of Cellular Biochemistry",
issn = "0730-2312",
publisher = "Wiley-Liss Inc.",
number = "6",

}

TY - JOUR

T1 - Lysophosphatidic acid production and action

T2 - Validated targets in cancer?

AU - Umezu-Goto, Makiko

AU - Tanyi, Janos

AU - Lahad, John

AU - Liu, Shuying

AU - Yu, Shuangxing

AU - Lapushin, Ruth

AU - Hasegawa, Yutaka

AU - Lu, Yiling

AU - Trost, Rosanne

AU - Bevers, Therese

AU - Jonasch, Eric

AU - Aldape, Ken

AU - Liu, Jinsong

AU - James, Robyn D.

AU - Ferguson, Colin G.

AU - Xu, Yong

AU - Prestwich, Glenn D.

AU - Mills, Gordon

PY - 2004/12/1

Y1 - 2004/12/1

N2 - The completion of the human genome project, the evolution of transcriptional profiling and the emergence of proteomics have focused attention on these areas in the pathophysiology and therapy of cancer. The role of lysophospholipids as potential mediators in cancer pathophysiology, screening and management has taken a major leap forward with the recent cloning of several enzymes involved in the metabolism of lysophospholipids. Lysophospholipids, although small molecules, contain a high "informational" content. Differences include the nature of the phosphate head group, the regiochemistry of the fatty acyl chain on the glyceryl backbone, the presence of ether versus ester linkages to the backbone, and the length and saturation of the fatty acyl or alkyl chain. This informational content is sufficient to result in a marked structure function activity relationship at their cognate receptors. Thus the emerging discipline of "functional lipidomics" is likely to prove as important as genomics and proteomics in terms of early diagnosis, prognosis, and therapy. Lysophospholipid levels are elevated in vivo in a number of pathophysiological states including ascitic fluid from ovarian cancer patients indicating a role in the pathophysiology of this devastating disease. Although controversial, levels of specific lysophospholipids may be altered in the blood of cancer patients providing a potential mechanism for early diagnosis. Several of the enzymes involved in the metabolism of lysophospholipids are aberrant in ovarian and other cancers. Further, the enzymes are active in the interstitial space, rendering them readily accessible to the effects of inhibitors including antibodies, proteins, and small molecules. In support of a role for lysophospholipids in the pathophysiology of cancer, expression of receptors for lysophospholipids is also aberrant in cancer cells from multiple different lineages. All of the cell surface receptors for lysophospholipids belong to the G protein coupled receptor family. As over 40% of all drugs in current use target this family of receptors, lysophospholipid receptors are highly "druggable." Indeed, a number of highly specific agonists and antagonists of lysophospholipid receptors have been identified. A number are in preclinical evaluation as therapeutics. We look forward to the next several years when the role of lysophospholipids in physiology and the pathophysiology and management of cancer and other diseases are fully elucidated.

AB - The completion of the human genome project, the evolution of transcriptional profiling and the emergence of proteomics have focused attention on these areas in the pathophysiology and therapy of cancer. The role of lysophospholipids as potential mediators in cancer pathophysiology, screening and management has taken a major leap forward with the recent cloning of several enzymes involved in the metabolism of lysophospholipids. Lysophospholipids, although small molecules, contain a high "informational" content. Differences include the nature of the phosphate head group, the regiochemistry of the fatty acyl chain on the glyceryl backbone, the presence of ether versus ester linkages to the backbone, and the length and saturation of the fatty acyl or alkyl chain. This informational content is sufficient to result in a marked structure function activity relationship at their cognate receptors. Thus the emerging discipline of "functional lipidomics" is likely to prove as important as genomics and proteomics in terms of early diagnosis, prognosis, and therapy. Lysophospholipid levels are elevated in vivo in a number of pathophysiological states including ascitic fluid from ovarian cancer patients indicating a role in the pathophysiology of this devastating disease. Although controversial, levels of specific lysophospholipids may be altered in the blood of cancer patients providing a potential mechanism for early diagnosis. Several of the enzymes involved in the metabolism of lysophospholipids are aberrant in ovarian and other cancers. Further, the enzymes are active in the interstitial space, rendering them readily accessible to the effects of inhibitors including antibodies, proteins, and small molecules. In support of a role for lysophospholipids in the pathophysiology of cancer, expression of receptors for lysophospholipids is also aberrant in cancer cells from multiple different lineages. All of the cell surface receptors for lysophospholipids belong to the G protein coupled receptor family. As over 40% of all drugs in current use target this family of receptors, lysophospholipid receptors are highly "druggable." Indeed, a number of highly specific agonists and antagonists of lysophospholipid receptors have been identified. A number are in preclinical evaluation as therapeutics. We look forward to the next several years when the role of lysophospholipids in physiology and the pathophysiology and management of cancer and other diseases are fully elucidated.

KW - Autotaxin

KW - Cancer

KW - Lysophosphatidic acid

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=5344266925&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=5344266925&partnerID=8YFLogxK

U2 - 10.1002/jcb.20113

DO - 10.1002/jcb.20113

M3 - Article

C2 - 15258897

AN - SCOPUS:5344266925

VL - 92

SP - 1115

EP - 1140

JO - Journal of Cellular Biochemistry

JF - Journal of Cellular Biochemistry

SN - 0730-2312

IS - 6

ER -